Close

Aimmune Therapeutics (AIMT) Completes Target Enrollment in AR101 Phase 3 PALISADE Trial

Go back to Aimmune Therapeutics (AIMT) Completes Target Enrollment in AR101 Phase 3 PALISADE Trial